Independence of HIF1a and androgen signaling pathways in prostate cancer

BACKGROUND: Therapeutic targeting of the androgen signaling pathway is a mainstay treatment for prostate cancer. Although initially effective, resistance to androgen targeted therapies develops followed by disease progression to castrate-resistant prostate cancer (CRPC). Hypoxia and HIF1a have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Maxine G. B., Bibby, Becky A. S., Yang, Lingjian, Lo, Franklin, Warren, Anne Y., Shukla, Deepa, Osborne, Michelle, Hadfield, James, Carroll, Thomas, Stark, Rory, Scott, Helen, Ramos-Montoya, Antonio, Massie, Charlie, Maxwell, Patrick, West, Catharine M. L., Mills, Ian G., Neal, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249645/
https://www.ncbi.nlm.nih.gov/pubmed/32450824
http://dx.doi.org/10.1186/s12885-020-06890-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249645/
https://www.ncbi.nlm.nih.gov/pubmed/32450824
http://dx.doi.org/10.1186/s12885-020-06890-6

Ejemplares similares